Trials / Completed
CompletedNCT05421013
Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC
An Open Label, Dose Escalation Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Subjects With Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Sirnaomics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open label, dose escalation to evaluate safety.
Detailed description
Evaluate safety, tolerability, and efficacy of various doses of STP705 administered as intralesional injection in subjects with facial isSCC. There will be 3 cohorts of 10 subjects each. Enrolled subjects will receive STP705 once weekly for 6 weeks. The lesion will be excised 60 days after.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | STP705 | STP705 targets TGFB-1 and COX-2 mRNA respectively. |
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2023-03-29
- Completion
- 2023-03-29
- First posted
- 2022-06-16
- Last updated
- 2024-03-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05421013. Inclusion in this directory is not an endorsement.